Arkolith/Insider Trading/ARWR/Form 4

Anzalone Christopher Richard

Chief Executive Officer, DirectorARROWHEAD PHARMACEUTICALS, INC. (ARWR) · full profile →Form 4 · filed Dec 23, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.8M
Net Open-Market Flow
-$1.8M
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 22, 2025Sell(S)3K$68.85$177K3.8M
Dec 22, 2025Sell(S)10K$68.33$684K3.8M
Dec 19, 2025Sell(S)4K$66.67$265K3.8M
Dec 19, 2025Sell(S)8K$68.01$554K3.8M
Dec 19, 2025Sell(S)1K$68.48$90K3.8M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001423029-25-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML